By demonstrating that inhibiting G4 assembly could potentially prevent the onset of synucleinopathies, this discovery positions G4 as a promising target for early intervention in these diseases.

Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, announces a groundbreaking paper in The Lancet Neurology. The study demonstrates the ...